More than £1 billion to be invested in UK science and research

More than £1 billion to be invested in UK science and research

30 October 2012

Seven new university and business research partnerships in sectors including life sciences, energy efficiency and advanced manufacturing were announced today by David Willetts, Minister for Universities and Science.

The new projects double the number of winning bids from the UK Research Partnership Investment Fund (UK RPIF) to 14. When complete, the scheme will deliver more than £1 billion of new funding for research from Government, industry and charities.

The 14 winning bids, which cover the whole of the UK, will take up £220 million of public funding and leverage in over £600 million of private support. There will shortly be a new bidding round for the remaining £80 million of public investment, and both new and resubmitted bids will be eligible.

David Willetts, Minister for Universities and Science, said:

    'It is fantastic that our top businesses and top charities are queuing up to collaborate with our world-class universities. They want to work together to deliver innovation, commercialisation and growth.

    'The winning projects will tackle the key issues we face – like fighting disease, ensuring energy efficiency and improving infrastructure – for the benefit of all.'

Sir Alan Langlands, Chief Executive of HEFCE, said:

    'The demand for funding from the UK Research Partnership Investment Fund demonstrates the power of universities in promoting economic growth through research and knowledge exchange. The support from international companies and world-leading charities – all making hard-headed investments – is a tribute to the excellence of scientific and research staff in our universities.'

The seven projects announced today are:

    A £38 million partnership between the University of Manchester, The Christie hospital and Cancer Research UK to develop the Manchester Cancer Research Centre. This will look at cancer treatments targeted to individuals based on the specific characteristics of their tumour biology. It will span laboratory research through to clinical trials, and patient care and focus on five research areas: radiation therapy, lung cancer, women's cancers, melanoma and haematological oncology.
    An £85 million partnership between UCL (University College London) and the Great Ormond Street Hospital. The Centre for Children's Rare Disease Research will combine the specialist research expertise of the UCL Institute of Child Health with the unique patient cohort at Great Ormond Street to find treatments and cures for rare diseases, of which over 6,000 have been identified.
    A £32 million partnership between Queen's University Belfast, The Atlantic Philanthropies, a Wellcome-Wolfson Capital Award, The Sir Jules Thorn Charitable Trust and the Insight Trust for the Visually Impaired to deliver the next phase of the Institute of Health Sciences. The Centre for Experimental Medicine will bring researchers working on vision sciences onto the campus alongside new research programmes in diabetes and genomics.
     A £34 million partnership between the University of Nottingham and GlaxoSmithKline to support the Centre of Excellence in Sustainable Chemistry. This will be housed within the new Carbon Neutral Laboratory, and will minimise environmental impact. It will ensure that chemistry becomes more energy- and resource-efficient and sustainable in meeting society's needs for better medicines, safer agrochemicals and new materials.
     A £38 million partnership between Swansea University, British Petroleum (BP), and TATA Steel Europe for the development of the Energy Safety Research Institute. This will capitalise on the university's strengths in petroleum and chemical processing, and focus on the safety issues surrounding the development of existing energy processes, as well as the safe deployment and integration of new green energy technologies.
    A £60 million partnership between Brunel University, TWI and other companies to develop a National Research Centre for Structural Integrity. This will act as a dedicated national hub for interdisciplinary research into the soundness of the design and constructions of products, plant and infrastructure across the energy, transport and advanced manufacturing.
    A £150 million partnership between Imperial College London and Voreda to contribute to the development of a major new campus adjacent to the White City regeneration area. The centrepiece will be the Research and Translation Hub, which will provide high-specification research and incubator space for 1,000 researchers investigating next-generation materials and spin-out companies.

UK RPIF was first launched with £100 million of public finance in May 2012. In response to the large number of high-quality bids, the Government has recently tripled the public support to £300 million. All projects have to include private funding from industry or the charitable sector worth a minimum of double the public contribution – making more than £1 billion of investment in total.

The 14 projects that have gained UK RPIF funding will provide a base for developing new knowledge to support economic growth, and to help meet the health needs of the UK and the wider world. Universities are contributing over £70 million from their own resources.

    The £300 million UK Research Partnership Investment Fund will provide investment in higher education research facilities. Universities are required to secure at least double the amount they receive from the fund from non-public sources.
    The UK RPIF was set up in 2012 and will allocate all funding across two funding rounds. It is managed by HEFCE, working in collaboration with devolved counterparts, with proposals assessed by an independent assessment panel. Funding awards are subject to further due diligence being conducted satisfactorily. Details of the UK RPIF are available on the HEFCE web-site.
    Despite enormous pressure on public spending the £4.6 billion per annum funding for science and research programmes has been protected in cash terms and ring-fenced against future pressures during the spending review period. The Government has now announced an extra £795 million of investment for science, research and innovation since the 2010 Spending Review.
    The first set of seven UK RPIF projects were announced by BIS and the Treasury on 8 October.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.